PMID- 30856108
OWN - NLM
STAT- MEDLINE
DCOM- 20190809
LR  - 20190809
IS  - 1875-869X (Electronic)
IS  - 1093-2607 (Linking)
VI  - 27
IP  - 2
DP  - 2019
TI  - Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid 
      antibody, and anticardiolipin antibody positivity on obstetrical complications 
      and pregnancy outcomes.
PG  - 135-141
LID - 10.3233/HAB-180359 [doi]
AB  - BACKGROUND: Extractable nuclear antigen (ENA) and anti-double stranded DNA 
      (anti-dsDNA) positivity and related diseases like systemic lupus erythematosus, 
      Sjogren syndrome, and other autoimmune diseases are known to be associated with 
      obstetrical complications and poor perinatal outcomes. OBJECTIVE: To demonstrate 
      the importance of ENA, anti-dsDNA, antiphospholipid (APL), and anticardiolipin 
      (ACL) antibody positivity on pregnancy outcomes. METHODS: Ninety one pregnant 
      women with known ENA, anti-dsDNA, APL IgG and IgM, and ACL IgG and IgM antibody 
      positivity were retrospectively compared with 91 randomly selected pregnant woman 
      in terms of obstetrical complications and pregnancy outcomes. Beksac Obstetrics 
      Index-pregnancy (BOIp), calculated as (number of children + (pi/10))/gravidity in 
      the current pregnancy, was used to compare the risk level between groups. 
      RESULTS: Significant differences were found in the median maternal age, 
      gravidity, number of previous miscarriages, and BOIp between the groups (p= 0.04, 
      p< 0.001, p< 0.001, and p< 0.001, respectively). Significant differences were 
      also found between the study and control groups in the median gestational age at 
      birth, birth weight, and APGAR1 score (p< 0.001 for all). Similarly, significant 
      differences were found between groups in the rates of intra-uterine growth 
      restriction, oligohydramnios, and gestational hypertension (p< 0.001, p= 0.05, 
      and p= 0.05, respectively). There were 3 (3.3%) stillbirths in the study group 
      and none in the control group (p= 0.123). CONCLUSION: We evaluated the impact of 
      anti-dsDNA, ENA, APL, and ACL antibody positivity, which may cause immunologic 
      inflammation at placenta and thereby affect pregnancy outcomes.
FAU - Tanacan, Atakan
AU  - Tanacan A
AD  - Division of Perinatology, Department of Obstetrics and Gynecology, Hacettepe 
      University, Ankara, Turkey.
FAU - Beksac, Mehmet Sinan
AU  - Beksac MS
AD  - Division of Perinatology, Department of Obstetrics and Gynecology, Hacettepe 
      University, Ankara, Turkey.
FAU - Orgul, Gokcen
AU  - Orgul G
AD  - Division of Perinatology, Department of Obstetrics and Gynecology, Hacettepe 
      University, Ankara, Turkey.
FAU - Duru, Sinem
AU  - Duru S
AD  - Division of Perinatology, Department of Obstetrics and Gynecology, Hacettepe 
      University, Ankara, Turkey.
FAU - Sener, Burcin
AU  - Sener B
AD  - Department of Clinical Biochemistry, Hacettepe University, Ankara, Turkey.
FAU - Karaagaoglu, Ergun
AU  - Karaagaoglu E
AD  - Department of Biostatistics, Hacettepe University, Ankara, Turkey.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Hum Antibodies
JT  - Human antibodies
JID - 9711270
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Antigens, Nuclear)
RN  - 0 (Immunoglobulins)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (RNA, Double-Stranded)
MH  - Abortion, Spontaneous/immunology
MH  - Adult
MH  - Antibodies, Anticardiolipin/*immunology
MH  - Antibodies, Antiphospholipid/*immunology
MH  - Antigens, Nuclear/*immunology
MH  - Antiphospholipid Syndrome/immunology
MH  - Autoimmune Diseases/immunology
MH  - Female
MH  - Fetal Growth Retardation/immunology
MH  - Gestational Age
MH  - Humans
MH  - Immunoglobulins/immunology
MH  - Lupus Coagulation Inhibitor/immunology
MH  - Lupus Erythematosus, Systemic/immunology
MH  - Placenta/immunology
MH  - Pregnancy
MH  - Pregnancy Complications/*immunology
MH  - Pregnancy Outcome
MH  - RNA, Double-Stranded/*immunology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stillbirth
MH  - Young Adult
OTO - NOTNLM
OT  - Pregnancy
OT  - anti-double stranded DNA
OT  - anticardiolipin antibody
OT  - antiphospholipid antibody
OT  - extractable nuclear antigen
OT  - perinatal morbidity and mortality
OT  - placental inflammation
EDAT- 2019/03/12 06:00
MHDA- 2019/08/10 06:00
CRDT- 2019/03/12 06:00
PHST- 2019/03/12 06:00 [pubmed]
PHST- 2019/08/10 06:00 [medline]
PHST- 2019/03/12 06:00 [entrez]
AID - HAB180359 [pii]
AID - 10.3233/HAB-180359 [doi]
PST - ppublish
SO  - Hum Antibodies. 2019;27(2):135-141. doi: 10.3233/HAB-180359.